NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy
NCT03224065 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 246
Last updated 2019-09-18
Summary
Treatment of non - tuberculosis mycobacteria lung disease is challenging. The current treatment used is from 2007 American Thoracic Society guidelines recommended antibiotic combination therapy, which is lack of validation of clinical studies. More and more studies have confirmed that NTM antibiotic resistant gene will affect the efficacy, such as erm(41), rrl to clarithromycin, rrs to amikacin and so on. This study aimed to compare the efficacy of guideline recommended therapy and optimized therapy according to antibiotic susceptibility - related genotype.Genetic testing is accomplished through GenSeizer's high-throughput gene capture technique.
Conditions
- Non - Tuberculosis Mycobacteria Lung Disease
Interventions
- DIAGNOSTIC_TEST
-
Genotype detected through GenSeizer high-throughput gene capture technology
The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
Sponsors & Collaborators
-
Shanghai Pulmonary Hospital, Shanghai, China
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 16 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-10-09
- Primary Completion
- 2020-09-30
- Completion
- 2020-09-30
Countries
- China
Study Locations
More Related Trials
-
TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
NCT00449644 ·Status: COMPLETED ·Phase: PHASE2
-
MDR Bacilli Surveillance and Clinical Feature in China
NCT02140853 ·Status: UNKNOWN
-
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
NCT00004689 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy
NCT00002085 ·Status: COMPLETED ·Phase: NA
-
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BLMZ Chinese Cohort
NCT07268664 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections
NCT06990126 ·Status: ENROLLING_BY_INVITATION
-
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
NCT07213765 ·Status: RECRUITING ·Phase: PHASE4
-
To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.
NCT00910871 ·Status: COMPLETED ·Phase: PHASE2
-
Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
NCT04677543 ·Status: COMPLETED ·Phase: PHASE3
-
mNGS Was Applied to the Study of Pathogen Identification, Precision Medication and Efficacy Evaluation of Infected Patients
NCT04310657 ·Status: UNKNOWN ·Phase: NA
-
Mycobacterium Avium Intracellulare Complex (MAC) Study
NCT00826423 ·Status: COMPLETED
-
Biomarkers of Phage Treatment Response in NTM and Other Infections
NCT07076238 ·Status: RECRUITING
-
An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
NCT02365623 ·Status: COMPLETED ·Phase: PHASE2
-
Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
NCT02120638 ·Status: UNKNOWN ·Phase: PHASE3
-
State of Play of Non-tuberculous Mycobacteria in Alsace
NCT06185166 ·Status: RECRUITING
-
Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections
NCT01097005 ·Status: COMPLETED
-
An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS
NCT00754273 ·Status: COMPLETED
-
Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
NCT00865280 ·Status: TERMINATED ·Phase: PHASE3
-
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
NCT02454205 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Antibiotics Resistance Gene in Healthcare Workers
NCT06228248 ·Status: COMPLETED
-
Trial of Antimycobacterial Therapy in Sarcoidosis
NCT01074554 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
T2Resistance - Detection of Resistance Related Genes
NCT05231187 ·Status: COMPLETED
-
Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment
NCT01072539 ·Status: COMPLETED
-
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
NCT01215851 ·Status: COMPLETED ·Phase: PHASE2
-
Impact MRSA -PCR on Patient Management
NCT03096405 ·Status: COMPLETED